Biocon to Reduce Workforce Amid Ongoing Biologics Merger Process

Biocon Trims Workforce as it Completes Integration of Biologics and Generics Businesses

Biocon, a Bengaluru-based biopharmaceutical company, is undergoing a workforce reduction as part of its organisational rationalisation following the merger of its biosimilar unit, Biocon Biologics, into the company as a wholly owned subsidiary. The move is not driven by cost-cutting measures, according to company sources.

The workforce reduction has been underway since early March, affecting employees across various ranks and functions, including research and development, quality, engineering, and support roles. Sources estimate that a few hundred employees have been impacted by the move, although the exact number is not publicly disclosed.

The separation process is being structured as a "mutually agreed decision," with employees voluntarily agreeing to end their employment relationship. Affected employees are being offered around three months' salary, along with variable pay, as severance. Employees were informed of separation decisions by human resources teams and asked to hand over company assets.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The rationalisation comes as Biocon completes the integration of its biologics and generics businesses, a $5.5-billion deal that has expanded the company's global footprint but also resulted in overlapping corporate functions and leadership roles. The combined entity is expected to operate under a simplified structure from April 1, when Shreehas Tambe takes over as chief executive officer and managing director.

Tambe has pushed back against suggestions that the exercise amounts to a broad-based layoff, stating that the integration was not driven by headcount reduction as a cost-saving objective. Instead, the focus remains on aligning talent and capabilities with strategy as the company transitions into a unified global medicines company spanning biosimilars, generics, and peptides.

Note: The table highlights the key differences in the integration impact on Biocon Biologics and Biocon.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline